

# Clinical trials of probucol

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>probucol vs control</b>			
FATS Fukosawa (probucol) , 2002 n=82/81 follow-up: 2 years	probucol 500 mg/day versus diet alone	asymptomatic patients with hypercholesterolemia	Parallel groups open Japan
<b>Probucol vs placebo</b>			
PQRST , 1994 n=152/151 follow-up: 3 ans	Probucol 1 g / j pendant 3 ans versus placebo, de mme aspect(2 tablettes par jour)pendant 3 ans	Stade II: 70%	Parallel groups Double aveugle
McCaughan , 1981 n=88/30 follow-up: 1 year	probucol versus placebo	hypercholesterolemic men	Parallel groups double-blind
PQRST , 1994 n=NA follow-up: 3 y	probucol 0.5 g twice daily versus placebo	hypercholesterolemic patients with visible atherosclerosis	Parallel groups double blind
Tardif , 1997 n=160/157 follow-up: 0.5 years	probucol 500 mg versus placebo	patients undergoing PTCA	Parallel groups open

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in patients with LDL elevation and without CHD at <http://www.trialresultscenter.org/go-Q5>
- cholesterol lowering intervention for cardiovascular prevention in patients with prior MI or with CHD at <http://www.trialresultscenter.org/go-Q12>
- cholesterol lowering intervention for cardiovascular prevention in all chronical situations at <http://www.trialresultscenter.org/go-Q154>

## References

### **FATS Fukosawa (probucol), 2002:**

Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002 Feb 20;39:610-6 [[11849859](#)]

### **PQRST, 1994:**

Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. Erikson U, Nilsson S, Stenport G Am J Cardiol 1988 Jul 25;62:44B-47B [[3293416](#)]

Holme I, Malmaeus I, Olsson AG, Nilsson S, Walladius G. Repeated measurements over time: statistical analysis of the angiographic outcomes in the Probucol Quantitative Regression Swedish Trial ( PQRST). Clinical Trials and Meta-Analysis 1993;28:95-108

Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Molgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C, et al Am J Cardiol 1988 Jul 25;62:37B-43B [[3293415](#)]

The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S, et al Am J Cardiol 1994 Nov 1;74:875-83 [[7977117](#)]

The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Regnstrom J, Nilsson J, Johansson J, Schafer-Elinder L, Moelgaard J, Hadell K, Olsson AG, Carlson LA Am J Cardiol 1993 Feb 25;71:15B-19B [[8434556](#)]

### **McCaughan, 1981:**

McCaughan D The long-term effects of probucol on serum lipid levels. Arch Intern Med 1981;141:1428-32 [[7025778](#)]

### **PQRST, 1994:**

Walldius G, Erikson U, Olsson AG, Bergstrand L, Hdell K, Johansson J, Kaijser L, Lassvik C, Mlgaard J, Nilsson S The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83 [[7977117](#)]

Walldius G, Regnstrm J, Nilsson J, Johansson J, Schfer-Elinder L, Moelgaard J, Hdell K, Olsson AG, Carlson LA The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1993;71:15B-19B [[8434556](#)]

Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Mlgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. Am J Cardiol 1988;62:37B-43B [[3293415](#)]

Walldius G, Erikson U, Olsson AG, Bergstrand L, Hdell K, Johansson J, Kaijser L, Lassvik C, Mlgaard J, Nilsson S The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83 [[7977117](#)]

### **Tardif, 1997:**

Tardif JC, Ct G, Lesprance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72 [[9241125](#)]

## 2 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
<b>dual sirolimus, probucol eluting stent vs sirolimus eluting stent</b>			
<b>ISAR TEST 2 (vs SES) , 2009</b> [NCT00332397] n=333/335 follow-up: 12 months	dual DES (polymer-free stent consisting of probucol and rapamycin) versus SES	patients with De novo lesions in native coronary arteries	Parallel groups open Germany
<b>dual sirolimus, probucol eluting stent vs zotarolimus eluting stent</b>			
<b>ISAR TEST 2 (vs ZES) , 2009</b> [NCT00332397] n=333/339 follow-up: 12 months	dual DES (polymer-free stent consisting of probucol and rapamycin) versus permanent polymer zotarolimus-eluting stent (Endeavor)	patients with De novo lesions in native coronary arteries	Parallel groups open Germany
<b>ISAR TEST 5</b> [NCT00598533] n=2002/1000 follow-up: 1 year	polymer-free, rapamycin/probucol-eluting Dual-DES stent versus zotarolimus-eluting stent with a modified permanent polymer on a cobalt-chromium alloy platform	"all-comers" population	Parallel groups

3

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at <http://www.trialresultscenter.org/go-Q26>
- Drug eluting stent for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q206>

## References

### ISAR TEST 2 (vs SES), 2009:

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schmig A, Kastrati A A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;: [19240066]

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schmig A, Kastrati A A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31 [19240066]

Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Piniack S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schmig A, Mehilli J 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. J Am Coll Cardiol 2010 Jun 8;55:2536-43 [20417052] 10.1016/j.jacc.2010.03.020

### ISAR TEST 2 (vs ZES), 2009:

Byrne RA ISAR-TEST 2: A prospective randomized trial comparing polymer-free rapamycin and probucol-eluting stents, polymer-based sirolimus-eluting stents, and zotarolimus-eluting stents in patients with coronary artery disease. TCT, October 16, 2008.

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schmig A, Kastrati A A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009 Feb 24; [19240066]

Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schmig A, Mehilli J 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. J Am Coll Cardiol 2010 Jun 8;55:2536-43 [20417052] 10.1016/j.jacc.2010.03.020

ISAR TEST 5, :

### 3 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
<b>probucol vs placebo</b>			
PQRST, 1994 n=152/151 follow-up: 3 ans	Probucol 1 g / j pendant 3 ans versus placebo, de mme aspect(2 tablettes par jour)pendant 3 ans	Stade II: 70%	Parallel groups Double aveugle

More details and results :

- cholesterol lowering intervention for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q52>

### References

#### PQRST, 1994:

Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. Erikson U, Nilsson S, Stenport G Am J Cardiol 1988 Jul 25;62:44B-47B [3293416]

Holme I, Malmaeus I, Olsson AG, Nilsson S, Walladius G. Repeated measurements over time: statistical analysis of the angiographic outcomes in the Probucol Quantitative Regression Swedish Trial ( PQRST). Clinical Trials and Meta-Analysis 1993;28:95-108

Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Molgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C, et al Am J Cardiol 1988 Jul 25;62:37B-43B [3293415]

The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S, et al Am J Cardiol 1994 Nov 1;74:875-83 [7977117]

The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Regnstrom J, Nilsson J, Johansson J, Schafer-Elinder L, Moelgaard J, Hadell K, Olsson AG, Carlson LA Am J Cardiol 1993 Feb 25;71:15B-19B [8434556]

Entry terms: Probucol, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir,